玻璃体腔内注射曲安奈德与贝伐单抗治疗白内障术后黄斑水肿的疗效

发布时间：2019-04-26 23:11

【摘要】：目的:评价曲安奈德和贝伐单抗玻璃体腔注射治疗白内障术后黄斑水肿的疗效,为临床安全有效用药提供参考。方法:选择2012-03/2014-03在我院眼科确诊为黄斑水肿的患者92例92眼为研究对象,按照玻璃体腔注射用药不同,分为曲安奈德组44例44眼和贝伐单抗组48例48眼术后随访9mo,比较两组患者在不同时间点的最佳矫正视力、黄斑中央视网膜平均厚度和眼内压情况。结果:术后随访9mo,两组患者术后的最佳矫正视力均比术前提高,但组间无统计学意义(P0.05);经重复测量方差分析,两组患者的黄斑中央视网膜厚度无统计学意义(P0.05)。曲安奈德组术后备时间点与术前的黄斑中央视网膜厚度差异具有统计学意义(t=9.16,8.27,5.44,5.87,4.62,P0.05),贝伐单抗组术后备时间点的斑中央视网膜厚度均比术前降低,具有统计学意义(t=8.11,5.12,4.16,3.27,2.88,P0.05);曲安奈德组有7例患者发生眼压升高,并发为青光眼,贝伐单抗组患者未见眼压异常。结论:曲安奈德和贝伐单抗均可提高黄斑水肿患者的矫正视力,改善毛细血管的渗漏情况,但贝伐单抗不会引起眼压升高,能避免其他并发症的发生,安全性更高。
[Abstract]:Aim: to evaluate the efficacy of intravitreal injection of triamcinolone acetonide and bevacumab in the treatment of macular edema after cataract surgery. Methods: 92 patients (92 eyes) with macular edema were divided into triamcinolone acetonide group (44 eyes, n = 44) and bevacumab group (48 eyes, n = 48). The best corrected visual acuity, central macular retinal thickness and intraocular pressure were compared between the two groups at different time points. Results: after 9 moa follow-up, the best corrected visual acuity of the two groups was improved after operation, but there was no significant difference between the two groups (P0.05). Repeated ANOVA showed no significant difference in central macular retinal thickness between the two groups (P0.05). The thickness of central macular retina in triamcinolone acetonide group was significantly different from that before operation (t = 9.16, 8.27, 5.44, 5.87, 4.62, P0.05). The thickness of central macular retina in bevacumab group was significantly lower than that before operation (t = 8.11,5.12,4.16,3.27,2.88, P0.05). In triamcinolone acetonide group, there were 7 patients with elevated IOP complicated with glaucoma, and no IOP abnormality was observed in bevacumab group. Conclusion: both triamcinolone acetonide and bevacumab can improve the corrected visual acuity and capillary leakage in patients with macular edema.
【作者单位】：中国山东省平邑县人民医院眼科;
【分类号】：R779.6

【参考文献】